In the DCVax-L trial, they of course have determined which patients were IDH-mutated. But you can’t pull them out, without pulling them from the 1200 to 1300 patients they will use as the external control arm for this trial because that data is not available for all those patients (maybe some, but not all of them). So you have to keep the IDH-mutated patients (my point has always been that there likely aren’t very many) in to make the comparison more equitable.
And if those patients performed well (lived longer)on DCVax, that theoretically could also be used to justify the use of DCVax-L in the future for IDH-mutated patients.
Market Data 
Markets 
AI
